Osteoclastogenesis-related genes

Osteoclastogenesis-related genes refer to a broad category of genetic factors that regulate the development, fusion, and activation of osteoclasts, the multinucleated cells responsible for bone resorption (PubMed: 29309106). This group is not a single therapeutic target but rather a collection of molecules including cytokines, receptors, and enzymes that maintain skeletal integrity through bone remodeling. Central to this process is the RANK/RANKL/OPG signaling axis, where the Receptor Activator of Nuclear Factor Kappa-B Ligand (RANKL) binds to its receptor RANK to trigger differentiation, a process modulated by the decoy receptor Osteoprotegerin (OPG) (NIH: NBK459207). Other critical genes in this set include the master transcription factor NFATc1 and functional proteins such as Cathepsin K and Tartrate-resistant acid phosphatase (TRAP) (UniProt: Q9GZV9). Dysregulation of these genes leads to an imbalance in bone turnover, contributing to pathologies such as osteoporosis, Paget's disease, and bone destruction in rheumatoid arthritis (StatPearls: NBK537112). Pharmacological intervention often targets specific members of this group; for instance, denosumab is a monoclonal antibody that inhibits RANKL, while bisphosphonates target the activity of the mature osteoclast (PubChem: CID 135311554).

Other names

Osteoclast differentiation genesBone resorption pathway genesOsteoclast markers

Inhibition of osteoclast differentiation via RANKL neutralization or direct inhibition of osteoclast activity and bone matrix degradation.